Henry Schein, Inc. (NASDAQ:HSIC) Short Interest Update

Henry Schein, Inc. (NASDAQ:HSIC) was the recipient of a large decline in short interest in the month of March. As of March 31st, there was short interest totalling 5,500,000 shares, a decline of 6.8% from the March 15th total of 5,900,000 shares. Based on an average daily trading volume, of 1,140,000 shares, the short-interest ratio is currently 4.8 days. Approximately 4.3% of the company’s stock are short sold.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Piper Sandler upped their target price on shares of Henry Schein from $78.00 to $86.00 and gave the company an “overweight” rating in a research note on Monday, February 26th. TheStreet upgraded Henry Schein from a “c+” rating to a “b-” rating in a research report on Monday, February 26th. Evercore ISI upped their price target on Henry Schein from $79.00 to $83.00 and gave the company an “in-line” rating in a research report on Wednesday, February 28th. JPMorgan Chase & Co. raised their price objective on Henry Schein from $82.00 to $88.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 6th. Finally, Barrington Research boosted their target price on shares of Henry Schein from $82.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, Henry Schein has an average rating of “Hold” and an average price target of $81.09.

Henry Schein Trading Down 1.4 %

Shares of NASDAQ:HSIC opened at $70.20 on Thursday. Henry Schein has a fifty-two week low of $60.01 and a fifty-two week high of $85.39. The company has a quick ratio of 1.00, a current ratio of 1.67 and a debt-to-equity ratio of 0.45. The company has a market cap of $9.02 billion, a PE ratio of 22.29, a P/E/G ratio of 1.75 and a beta of 0.87. The company’s 50-day moving average price is $74.53 and its 200 day moving average price is $72.50.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, February 27th. The company reported $0.66 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.04). Henry Schein had a return on equity of 14.03% and a net margin of 3.37%. The business had revenue of $3.02 billion for the quarter, compared to analyst estimates of $3 billion. During the same quarter in the prior year, the firm posted $1.21 earnings per share. The business’s quarterly revenue was down 10.5% on a year-over-year basis. Sell-side analysts anticipate that Henry Schein will post 5.07 earnings per share for the current year.

Insider Buying and Selling

In other Henry Schein news, Vice Chairman James P. Breslawski sold 2,907 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $74.37, for a total value of $216,193.59. Following the completion of the transaction, the insider now directly owns 209,562 shares of the company’s stock, valued at approximately $15,585,125.94. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, CEO Bradford C. Connett sold 6,430 shares of Henry Schein stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total value of $477,620.40. Following the completion of the sale, the chief executive officer now owns 73,108 shares in the company, valued at $5,430,462.24. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Vice Chairman James P. Breslawski sold 2,907 shares of the company’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $74.37, for a total transaction of $216,193.59. Following the completion of the sale, the insider now directly owns 209,562 shares in the company, valued at $15,585,125.94. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Henry Schein

Several institutional investors have recently bought and sold shares of the stock. Cambridge Investment Research Advisors Inc. lifted its stake in shares of Henry Schein by 2.4% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 5,262 shares of the company’s stock worth $459,000 after acquiring an additional 122 shares during the period. Aurora Investment Counsel lifted its holdings in shares of Henry Schein by 0.7% in the third quarter. Aurora Investment Counsel now owns 20,641 shares of the company’s stock valued at $1,533,000 after buying an additional 140 shares during the period. Arizona State Retirement System boosted its stake in Henry Schein by 0.4% during the fourth quarter. Arizona State Retirement System now owns 35,890 shares of the company’s stock valued at $2,717,000 after buying an additional 149 shares in the last quarter. Studio Investment Management LLC grew its holdings in Henry Schein by 3.9% during the fourth quarter. Studio Investment Management LLC now owns 4,160 shares of the company’s stock worth $332,000 after acquiring an additional 155 shares during the period. Finally, Kentucky Retirement Systems Insurance Trust Fund raised its position in Henry Schein by 3.4% in the third quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 4,878 shares of the company’s stock worth $321,000 after acquiring an additional 161 shares in the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.